The American Cancer Society estimates that 44,000 new cases of pancreatic cancer will be diagnosed this year and that 37,000 people will die from the disease. These are not strong odds. A new drug, rigosertib, allows pancreatic cancer cells to rush through replication — and then stops them cold, killing them in in the middle of a step called M phase. Healthy cells that don’t rush are unharmed.